Jazz Pharmaceuticals plc (JAZZ) stock
JAZZNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 2, 2026Score 7/30119% above fair value
$241.55+1.18 (+0.49%)
Close on Nov 13, 2026Market cap $15.68BP/E 78.7Yield –
Jazz Pharmaceuticals ebitda
EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.
For fiscal 2025 it was -$388.64M, down 151.9% from the year before. The highest annual figure on record is $749.43M in fiscal 2024.
Annual ebitda
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$388.64M | -151.9% |
| FY2024 | Dec 31, 2024 | $749.43M | +23.1% |
| FY2023 | Dec 31, 2023 | $608.98M | – |
| FY2022 | Dec 31, 2022 | -$35.23M | -117.9% |
| FY2021 | Dec 31, 2021 | $196.98M | -50.4% |
| FY2020 | Dec 31, 2020 | $396.77M | -27.6% |
| FY2019 | Dec 31, 2019 | $547.67M | -13.1% |
| FY2018 | Dec 31, 2018 | $630.04M | +16.3% |
| FY2017 | Dec 31, 2017 | $541.94M | -10.2% |
| FY2016 | Dec 31, 2016 | $603.45M | +16.5% |
| FY2015 | Dec 31, 2015 | $518.12M | – |
See a number that looks wrong?